Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 70 years or older
- People who have not previously received any treatment for diffuse large B-cell lymphoma (DLBCL)
- People who have been confirmed by laboratory tissue testing to have a specific type of DLBCL called "DLBCL, not otherwise specified" that is CD20-positive, shows high levels of two proteins called MYC and BCL2 under testing, and is not classified as "double-hit" or "triple-hit" lymphoma
- People whose scans (a type of specialised body scan called a PET-CT) show at least one area of active lymphoma detectable by the scan
- People whose lymphoma is rated above a score of 1 on a standard medical risk scale called the International Prognostic Index (IPI)
- People who are reasonably physically active and able to carry out daily activities, as measured by a standard medical scale (rated 0, 1, or 2 out of 5 on this scale)
- People whose blood and organ function test results at the start of the trial meet specific levels for red blood cells, white blood cells, platelets, kidney function, liver function, and bilirubin (confirm exact values with trial site)
- People expected to live for at least 6 months
- People who understand the trial and are willing to sign a written consent form
Who may not be able to join:
- People whose lymphoma has spread to the brain or spinal cord
- People whose lymphoma developed by transforming from a different type of lymphoma (such as follicular lymphoma or others), or who have certain specific subtypes of DLBCL (such as primary brain DLBCL)
- People with uncontrolled heart or blood vessel disease, blood clotting disorders, autoimmune diseases, or serious active infections
- People who have had a severe allergic reaction to certain types of antibody-based medicines, or who have known sensitivities or allergies to any of the drugs used in this trial
- People with HIV or hepatitis C (HCV) infection
- People with certain hepatitis B (HBV) results — eligibility depends on specific hepatitis B blood test results, so the trial site would need to assess this individually (confirm with trial site)
- People who are unable to follow the trial procedures due to psychiatric illness or other reasons
- Women who are pregnant or breastfeeding
- Women who could become pregnant, or men whose partners could become pregnant, who are unwilling or unable to use effective contraception during treatment and for a defined period after the last dose of trial medication
- People with any other condition the trial doctors consider would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ou Bai, PHD, The First Bethune Hospital of Jilin University
Phone: 13039046656
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.